Chemotherapy News and Research

Latest Chemotherapy News and Research

Ovarian cancer molecular updates

In a new study a genetic mutation was found in the most common form of ovarian cancer. This according to the US scientists could pave the way for a more effective treatment of the disease. The detailed genetic map already helped scientists identify existing drugs with the potential for treating the mutations found in ovarian cancer tumors and also identified mutations that could respond to new drugs.

1 Jul 2011

Avastin for breast cancer still covered by Medicare despite FDA indecision

The Medicare will continue to cover Avastin for breast cancer treatment even if U.S. Food and Drug Administration Commissioner Peggy Hamburg decides to withdraw Avastin for such use, according to Don McLeod, a spokesman for the Centers for Medicare and Medicaid. McLeod said, in his statement, “The FDA decision, when it comes, does not affect CMS.”

1 Jul 2011

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Accelerated Community Oncology Research Network, Inc., reported positive results of a large double-blind, randomized Phase 2b trial in patients with breast cancer at the American Society of Clinical Oncology (ASCO) 47th annual meeting in Chicago, June 3-7.

1 Jul 2011

Molecular radiotherapy offers hope for children with neuroblastoma

A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine.

30 Jun 2011

New technology reduces stress of scheduling chemotherapy treatments

The stress of scheduling chemotherapy treatments has been substantially reduced by a new technology created and implemented by a team of researchers from the Sauder School of Business at the University of British Columbia and the BC Cancer Agency.

30 Jun 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

FDA looks at Avastin risks

The US Food and Drug Administration is holding a two-day hearing that pits the FDA's Center for Drug Evaluation and Research against Genentech, that manufactures breast cancer drug Avastin. A handful of breast cancer patients testified Tuesday that Avastin helped in treating their metastatic breast cancer but a review of studies conducted by the FDA's Center for Drug Evaluation and Research suggests the risks outweigh the benefits of Avastin for treating breast cancer, FDA officials said at the hearing.

29 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.

28 Jun 2011

Women can benefit from immediate breast reconstruction following mastectomy

For women undergoing mastectomy for breast cancer, immediate breast reconstruction has a low risk of complications—including serious complications related to radiation therapy—and does not cause undue delays in cancer treatment, reports a study in the July issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

28 Jun 2011

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Leading researchers and policy experts from across the country will come together June 27 and June 28 at Mount Sinai School of Medicine in New York to examine the issue of declining enrollment in clinical trials.

28 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

Seattle Genetics, Inc., today announced that it will receive a $5 million milestone payment under its brentuximab vedotin (ADCETRIS) collaboration with Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

27 Jun 2011

Biota reports preliminary data from CS-8958 Phase III trial against influenza

Dr Seizaburo Kashiwagi presented the preliminary data from an influenza Phase III prophylaxis study conducted during the 2009/2010 pandemic flu season in Japan.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

Astronomers to develop potential new cancer radiation treatment

Astronomers' research on celestial bodies may have an impact on the human body. Ohio State University astronomers are working with medical physicists and radiation oncologists to develop a potential new radiation treatment - one that is intended to be tougher on tumors, but gentler on healthy tissue.

27 Jun 2011

New model of health care delivery relies on active participation of patients and caregivers

A new model of care developed for patients at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS) has led to improved patient experience, lower costs and better patient outcomes.

24 Jun 2011

Longer looks: Prenatal care for dads; rise in bipolar diagnosis for children

Perhaps it's because mom has the burgeoning belly, but dads have largely been left out of prenatal care. That could be damaging to the family's health, contends research in a recent issue of the Journal of Advanced Nursing.

24 Jun 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Ovarian cancer molecular updates

Avastin for breast cancer still covered by Medicare despite FDA indecision

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Molecular radiotherapy offers hope for children with neuroblastoma

New technology reduces stress of scheduling chemotherapy treatments

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

FDA looks at Avastin risks

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Women can benefit from immediate breast reconstruction following mastectomy

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

Biota reports preliminary data from CS-8958 Phase III trial against influenza

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

Astronomers to develop potential new cancer radiation treatment

New model of health care delivery relies on active participation of patients and caregivers

Longer looks: Prenatal care for dads; rise in bipolar diagnosis for children

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in